Cytosorbents Business Summary

CytoSorbents Corporation (CTSO) is a commercial-stage medical device leader specializing in extracorporeal blood purification via its proprietary adsorbent polymer technology. The company generates revenue through a high-margin "razor-and-blade" model, selling single-use CytoSorb and DrugSorb-ATR cartridges that are compatible with most existing hospital dialysis, CRRT, and heart-lung machines. Its business is segmented into direct sales—primarily in Germany and the DACH region—and an international distributor network spanning over 75 countries. As of March 2026, the company is executing a strategic pivot toward the U.S. market, supported by a Q1 2026 De Novo FDA submission for DrugSorb-ATR and a target of achieving operational cash flow breakeven. CytoSorbents competes with Baxter International (Oxiris), Fresenius Medical Care (CytoPore), and ExThera Medical (Seraph 100), distinguishing itself through its platform-agnostic design and broad-spectrum capability to remove both cytokines and antithrombotic drugs during emergency surgery. The leadership team is anchored by Co-founder and CEO Dr. Phillip Chan, who has led the company’s transition from R&D to global commercialization over a 17-year tenure. He is supported by CFO Peter J. Mariani, a seasoned medical device executive formerly of Axogen and Guidant, and President and COO Vincent Capponi, who brings over two decades of operational experience from Upjohn and Sabratek. Clinical and regulatory initiatives are spearheaded by CMO Dr. Efthymios Deliargyris, an interventional cardiologist who managed the pivotal STAR-T and STAR-D clinical programs. The Board of Directors, chaired by Michael Bator (formerly of Jennison Associates), provides deep capital markets expertise, while institutional support from Vanguard Group and debt financing from Avenue Capital Group provide the liquidity necessary to reach 2026 regulatory milestones.